



Supplementary Material

New arylethanolimidazole derivatives as HO-1 inhibitors with cytotoxicity against MCF-7 breast cancer cells

Valeria Ciaffaglione¹, Sebastiano Intagliata^{1,*}, Valeria Pittalà¹, Agostino Marrazzo¹, Valeria Sorrenti¹, Luca Vanella¹ Antonio Rescifina^{1,2}, Giuseppe Floresta^{1,3}, Ameera Sultan⁴, Khaled Greish⁴, and Loredana Salerno^{1,*}

¹ Department of Drug Sciences, University of Catania, viale A. Doria 6, 95125, Catania, Italy; valeria.ciaffaglione@phd.unict.it (V.C.); s.intagliata@unict.it (S.I.); vpittala@unict.it (V.P.); marrazzo@unict.it (A.M.); sorrenti@unict.it (V.S.); ivanella@unict.it (L.V.); arescifina@unict.it (A.R.); giuseppe.floresta@unict.it (G.F.); l.salerno@unict.it (L.S.)

² Consorzio Interuniversitario Nazionale di ricerca in Metodologie e Processi Innovativi di Sintesi (C.I.N.M.P.S.), Via E. Orabona, 4, 70125 Bari, Italy

³ Institute of Pharmaceutical Science, King's College London, Stamford Street, London SE1 9NH, UK

⁴ Department of Molecular Medicine, College of Medicine and Medical Sciences, Princess Al-Jawhara Centre for Molecular Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain; ameeraaa@agu.edu.bh (A.S.); khaledfg@agu.edu.bh (K.G.)



* Correspondence: s.intagliata@unict.it (S.I.); l.salerno@unict.it (L.S.); Tel.: +39-095-738-4053 (S.I.); +39-095-738-4266 (L.S.)



Table of contents

Table S1: Elemental analysis data for compounds 2a–c , 5a–f , and 6a,b .	S2
Figures S1–S22: ¹ H NMR and ¹³ C NMR spectra of compounds 2a–c , 5a–f , and 6a,b .	S3–S13
Figures S23–S25: Binding mode of compounds 2a–c , 5a–f , and 6a,b .	S14–S15
Figures S26–S36: 2D interactions of compounds 2a–c , 5a–f , and 6a,b .	S15–S20

Table S1. Elemental analysis data for compounds **2a–c**, **5a–f**, and **6a,b**.

Compd	Formula	Mw	Calcd			Found		
			C	H	N	C	H	N
2a	C ₁₁ H ₁₁ BrN ₂	251.12	52.61	4.42	11.16	52.69	4.48	11.19
2b	C ₁₈ H ₁₇ BrN ₂ O ₂	357.24	60.52	4.80	7.84	60.48	4.86	7.80
2c	C ₁₇ H ₁₆ N ₂	248.32	82.22	6.49	11.28	82.25	6.54	11.33
5a	C ₁₈ H ₁₇ BrN ₂ O ₂	373.24	57.92	4.59	7.51	57.95	4.62	7.55
5b	C ₁₈ H ₁₇ BrN ₂ O ₂	373.24	57.92	4.59	7.51	57.89	4.64	7.53
5c	C ₁₈ H ₁₇ BrN ₂ O ₂	373.24	57.92	4.59	7.51	57.96	4.64	7.56
5d	C ₁₈ H ₁₇ BrN ₂ O ₂	373.24	57.92	4.59	7.51	57.94	4.63	7.49
5e	C ₁₈ H ₁₇ BrN ₂ O ₂	373.24	57.92	4.59	7.51	57.96	4.57	7.53
5f	C ₁₈ H ₁₇ BrN ₂ O ₂	373.24	57.92	4.59	7.51	57.94	4.61	7.48
6a	C ₁₈ H ₁₆ BrClN ₂ O	391.69	55.19	4.12	7.15	55.17	4.10	7.19
6b	C ₁₈ H ₁₅ BrCl ₂ N ₂ O	426.13	50.73	3.55	6.57	50.77	3.59	6.53

**Figure S1.** ^1H NMR of compound **2a**.**Figure S2.** ^{13}C NMR of compound **2a**.

**Figure S3.** ^1H NMR of compound **2b**.**Figure S4.** ^{13}C NMR of compound **2b**.




Figure S5. ¹H NMR of compound 2c.














Figure S6. ¹³C NMR of compound 2c.



**Figure S7.** ¹H NMR of compound 5a.**Figure S8.** ¹³C NMR of compound 5a.

**Figure S9.** ^1H NMR of compound **5b**.**Figure S10.** ^{13}C NMR of compound **5b**.

**Figure S11.** ¹H NMR of compound 5c.**Figure S12.** ¹³C NMR of compound 5c.

**Figure S13.** ^1H NMR of compound **5d**.**Figure S14.** ^{13}C NMR of compound **5d**.

**Figure S15.** ^1H NMR of compound 5e.**Figure S16.** ^{13}C NMR of compound 5e.

**Figure S17.** ¹H NMR of compound 5f.**Figure S18.** ¹³C NMR of compound 5f.




Figure S19. ^1H NMR of compound **6a**.




Figure S20. ^{13}C NMR of compound **6a**.




Figure S21. ^1H NMR of compound **6b**.




Figure S22. ^{13}C NMR of compound 6b.




Figure S23. Binding poses of molecules **2a–c** (green) compared to the crystallized pose of QC-15 (white).




Figure S24. Binding poses of molecules **5b–f** (green) compared to the crystallized pose of QC-15 (white). In yellow the binding pose of the most potent compound **5a**.




Figure S25. Binding poses of molecules **6a, b** (green) compared to the crystallized pose of QC-15 (white).




Figure S26. 2D representations of HO-1-molecule **2a** complex.




Figure S7. 2D representations of HO-1-molecule **2b** complex.




Figure S28. 2D representations of HO-1-molecule **2c** complex.




Figure S29. 2D representations of HO-1-molecule **5a** complex.




Figure S30. 2D representations of HO-1-molecule **5b** complex.




Figure S31. 2D representations of HO-1-molecule **5c** complex.




Figure S32. 2D representations of HO-1-molecule **5d** complex.




Figure S33. 2D representations of HO-1-molecule **5e** complex.




Figure S34. 2D representations of HO-1-molecule **5f** complex.




Figure S35. 2D representations of HO-1-molecule **6a** complex.




Figure S36. 2D representations of HO-1-molecule **6b** complex.